BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …

Background: The presence of a telomerase reverse transcriptase (TERT) promoter mutation
has been suggested as a potential prognostic marker for thyroid cancer, and a synergistic …

Introduction The use of molecular markers, especially BRAF and TERT promoter mutations,
for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In …

In this study, we examined the relationship between coexisting BRAF V600E and TERT
promoter mutations in papillary thyroid cancer (PTC) and response to therapy. PTC cases …

Purpose To investigate the prognostic value of the BRAF V600E mutation and the recently
identified TERT promoter mutation chr5: 1,295,228 C> T (C228T), individually and in their …

TO THE EDITOR: We read with interest the study by Xing et al 1 recently published inJournal
of Clinical Oncology, together with the accompanying editorial. 2 In their large series of …

The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the
aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we …

Background The BRAF V600E and telomerase reverse transcriptase (TERT) promoter
mutations have been reported in papillary thyroid carcinoma (PTC). The aim of this …

Background To determine the relevance of the single or combination mutations of BRAF
V600E, TERT, and NRAS genes and the clinicopathologic relationship in papillary thyroid …

The prognostic role of molecular markers in papillary thyroid carcinoma (PTC) is a matter of
ongoing debate. The aim of our study is to investigate the impact of RAS, BRAF, TERT …